Ravi Radhakrishnan
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (20)
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
There is an unmet need to classify cancer-promoting kinase mutations in a mechanistically cognizant way. The challenge is to understand how mutations stabilize different kinase configurations to alter function, and how this influences pathogenic potential of the kinase and its responses to therapeutic inhibitors. This goal is made more challenging by the complexity of the mutational landscape of diseases, and is further compounded by the conformational plasticity of each variant where multiple conformations coexist. We focus here on the human MEK1 kinase, a vital component of the RAS/MAPK pathway in which mutations cause cancers and developmental disorders called RASopathies. We sought to explore how these mutations alter the human MEK1 kinase at atomic resolution by utilizing enhanced sampling simulations and free energy calculations. We computationally mapped the different conformational stabilities of individual mutated systems by delineating the free energy landscapes, and showed how this relates directly to experimentally quantified developmental transformation potentials of the mutations. We conclude that mutations leverage variations in the hydrogen bonding network associated with the conformational plasticity to progressively stabilize the active-like conformational state of the kinase while destabilizing the inactive-like state. The mutations alter residue-level internal molecular correlations by differentially prioritizing different conformational states, delineating the various modes of MEK1 activation reminiscent of a gear-shifting mechanism. We define the molecular basis of conversion of this kinase from its inactive to its active state, connecting structure, dynamics, and function by delineating the energy landscape and conformational plasticity, thus augmenting our understanding of MEK1 regulation.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2020
Collaborators (6)
Daniel Abler
University Hospital of Geneva
Mark Lemmon
Alfred Gilman Professor and Co-Director
Yale University School of Medicine
Cesar de la Fuente‐Nunez
-
Philippe Büchler
Professor
University of Bern
Baofu Qiao
Assistant Professor
Baruch College
Felipe Jimenez
Research Associate Professor
Northwestern University
Make your next move.
Prepare your application
Review drafts before you send them.